Table 1.
Main characteristics of the 96 the patients upon entry to the ICU (intensive care unit).
| With intubationa | Without intubationa | Totala | |
|---|---|---|---|
| Patients, n (%) | 71 (79.0%) | 20 (22.0%) | 96 (100%) |
| Women, n (%) | 14 (19.7%) | c | 20 (20.8%) |
| Age, mean (min-max) | 63.4 (20-85) | 63.8 (34-89) | 63.4 (20-89) |
| Comorbidities, n (%)b | |||
| Cardiovascular disease | |||
| Arterial hypertension | 32 (45.1%) | 7 (35.0%) | 43 (44.8%) |
| Rhythmic Heart disease | 5 (7.0%) | c | 6 (6.3%) |
| Other cardiovascular diseases | 10 (14.1%) | 5 (25.0%) | 16 (16.7%) |
| Chronic respiratory disease | |||
| Asthma | 6 (8.5%) | 0 | 6 (6.3%) |
| Chronic obstructive pulmonary disease | c | c | 5 (5.2%) |
| Kidney disease (or kidney transplant) | 7 (9.9%) | c | 10 (10.4%) |
| Metabolic disorders | |||
| Overweight or Obesity | 51 (71.8%) | 10 (50%) | 64 (66.6%) |
| Body mass index, median (min-max) | 28.1 (20-47) | 26.6 (19-42) | 28.0 (19-47) |
| Dyslipidaemia disorders | 12 (16.9%) | c | 15 (15.6%) |
| Diabetes | 16 (22.5%) | 7 (35.0%) | 27 (28.1%) |
| Cancer (solid or hematologic) | 6 (8.5%) | c | 10 (10.4%) |
| Current smokers | c | c | 6 (6.3%) |
| Total Comorbidities | |||
| 1 | 12 (16.9%) | c | 13 (13.5%) |
| ≥2 | 54 (76.1%) | 15 (75.0%) | 74 (77.1%) |
| Median (min-max) | 3 (0-7) | 3 (0-5) | 3 (0-7) |
| Drug exposure before ICU admission | |||
| Paracetamol | 24 (33.8%) | c | 31 (32.1%) |
| Nonsteroidal anti-inflammatory drugs | 5 (7%) | 0 | 6 (6.3%) |
| Corticosteroid drugs | 11 (15.5%) | c | 13 (13.5%) |
| Other immunosuppressant drugs | 5 (7.0%) | c | 6 (6.3%) |
| Cardiovascular drugs | |||
| ACEIs | 6 (8.5%) | c | 12 (12.5%) |
| ARBs | 20 (28.2%) | c | 23 (24.0%) |
| Diuretics | 10 (14.1%) | c | 15 (15.6) |
| CCBs | 11 (15.5%) | c | 13 (13.5%) |
| Beta-blockers | 9 (12.9%) | c | 14 (14.6%) |
| Statins | 6 (8.5%) | c | 11 (11.5%) |
| Antiplatelet drugs | 8 (11.3%) | c | 10 (10.4%) |
| Anti-hyperglycaemic drugs | |||
| Metformin | 10 (14.1%) | c | 16 (16.7%) |
| Glicazide | c | c | 5 (5.4%) |
| DDP4 inhibitors | 5 (7.0%) | c | 10 (10.4%) |
| Insulin | 6 (8.5%) | c | 11 (11.5%) |
| PPIs | 8 (11.3%) | c | 12 (12.5%) |
| Beta2 adrenergic receptor agonists | 5 (7.0%) | c | 9 (9.4%) |
| Benzodiazepine | 5 (7.0%) | c | 7 (7.3%) |
| Total drugs | |||
| None | 10 (14.1%) | c | 12 (12.5%) |
| [1-3] | 31 (43.7%) | 9 (45%) | 42 (43.8%) |
| ≥4 | 30 (32.2%) | 9 (55%) | 42 (43.8%) |
| Median (min-max) | 3 (0-14) | 3 (0-8) | 3 (0-14) |
| Time between first symptoms and ICU admission, median (days) | 9 (1-37) | 7 (0-20) | 8 (0-37) |
| Hospitalisation time in ICU, median (days) | 14 (3-33) | 3 (0-13) | 10 (1-33) |
| Death | 8 (11.3%) | c | 9 (9.3%) |
ARBs: angiotensin II receptor blockers; ACEIs: angiotensin converting enzyme inhibitors; CCBs: calcium channel blockers; ICU: intensive care unit; PPIs: proton pump inhibitors.
a
The clinical outcomes were not available for 5 patients on the April 21, 2020, as they were still hospitalised.
b
There were less than 5 patients with auto-immune diseases, liver disease or depression.
c
Number of patients <5.